First Time Loading...

Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 161.96 USD 0.36%
Updated: Mar 1, 2024

Intrinsic Value

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. [ Read More ]

The intrinsic value of one JNJ stock under the Base Case scenario is 168.13 USD. Compared to the current market price of 161.96 USD, Johnson & Johnson is Undervalued by 4%.

Key Points:
JNJ Intrinsic Value
Base Case
168.13 USD
Undervaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Johnson & Johnson

Backtest JNJ Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling JNJ stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Johnson & Johnson's Strong 2023 Sales Growth
2023-Q4 Earnings Call

Johnson & Johnson's Strong 2023 Sales Growth

In Q4 2023, Johnson & Johnson saw worldwide sales of $21.4 billion, up 7.2%, with U.S. growth outpacing international at 11% versus 2.7%. The company's full-year sales reached $85.2 billion, marking a 7.4% increase, and adjusted net earnings rose 6.8% to $25.4 billion. Innovative Medicine's sales grew by 4%, driven by key brands like DARZALEX and ERLEADA, despite losses in exclusivity for ZYTIGA in Europe. MedTech sales surged 13.4% to $7.7 billion, bolstered by the Abiomed acquisition and strong growth in Electrophysiology, though partially offset by Russia sanctions. Margins were pressured by commodity inflation and an unfavorable product mix in MedTech, mitigated by lower costs in Innovative Medicine. R&D investment remained substantial at $4.5 billion.

Financials

Balance Sheet Decomposition
Johnson & Johnson

Current Assets 53.7B
Cash & Short-Term Investments 23.5B
Receivables 14.8B
Other Current Assets 15.4B
Non-Current Assets 112.4B
Long-Term Investments 4B
PP&E 18.8B
Intangibles 71.1B
Other Non-Current Assets 18.4B
Current Liabilities 44.4B
Accounts Payable 8.4B
Accrued Liabilities 29.2B
Short-Term Debt 2B
Other Current Liabilities 4.8B
Non-Current Liabilities 50.5B
Long-Term Debt 26.1B
Other Non-Current Liabilities 24.4B
Efficiency
Fundamental Scores

JNJ Profitability Score
Profitability Due Diligence

Johnson & Johnson's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Exceptional 3-Year Average ROE
Exceptional ROE
68/100
Profitability
Score

Johnson & Johnson's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

JNJ Solvency Score
Solvency Due Diligence

Johnson & Johnson's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Positive Net Debt
64/100
Solvency
Score

Johnson & Johnson's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

JNJ Price Targets Summary
Johnson & Johnson

Wall Street analysts forecast JNJ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JNJ is 178.55 USD with a low forecast of 158.57 USD and a high forecast of 225.75 USD.

Lowest
Price Target
158.57 USD
2% Downside
Average
Price Target
178.55 USD
10% Upside
Highest
Price Target
225.75 USD
39% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

JNJ Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

JNJ Price
Johnson & Johnson

1M 1M
+2%
6M 6M
+1%
1Y 1Y
+7%
3Y 3Y
+8%
5Y 5Y
+31%
10Y 10Y
+127%
Annual Price Range
161.96
52w Low
145.6
52w High
174.48
Price Metrics
Average Annual Return 9.22%
Standard Deviation of Annual Returns 2.56%
Max Drawdown -27%
Shares Statistics
Market Capitalization 390.7B USD
Shares Outstanding 2 408 770 048
Percentage of Shares Shorted 0.51%

JNJ Return Decomposition
Main factors of price return

What is price return decomposition?

JNJ News

Other Videos

Last Important Events
Johnson & Johnson

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Johnson & Johnson

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Johnson & Johnson Logo
Johnson & Johnson

Country

United States of America

Industry

Pharmaceuticals

Market Cap

390.7B USD

Dividend Yield

2.94%

Description

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in New Brunswick, New Jersey and currently employs 141,700 full-time employees. The firm operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.

Contact

NEW JERSEY
New Brunswick
One Johnson & Johnson Plaza
+17325242455.0
https://www.jnj.com/

IPO

1944-09-25

Employees

141 700

Officers

CEO & Chairman
Mr. Joaquin Duato
Executive VP & CFO
Mr. Joseph J. Wolk CPA
Controller & Chief Accounting Officer
Mr. Robert J. Decker Jr.
Executive VP & Chief Information Officer
Mr. James Swanson
Vice President of Investor Relations
Ms. Jessica Moore
Chief Compliance Officer
Mr. Dirk Brinckman
Show More
Executive VP & General Counsel
Ms. Elizabeth Forminard
Executive VP & Chief Human Resources Officer
Dr. Peter M. Fasolo Ph.D.
Group Chairman of MD&D Business - EMEA
Dr. Guy J. Lebeau M.D.
Executive VP, Chief External Innovation & Medical Officer
Dr. William N. Hait M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one JNJ stock?

The intrinsic value of one JNJ stock under the Base Case scenario is 168.13 USD.

Is JNJ stock undervalued or overvalued?

Compared to the current market price of 161.96 USD, Johnson & Johnson is Undervalued by 4%.